BRKR Bruker Corporation logo

BRKR Bruker Corporation

Healthcare
$45.69+1.58%ClosedMarket Cap: $6.96B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

2.84

P/S

2.01

EV/EBITDA

26.77

DCF Value

$49.35

FCF Yield

0.7%

Div Yield

0.4%

Margins & Returns

Gross Margin

45.6%

Operating Margin

5.9%

Net Margin

-0.3%

ROE

-0.5%

ROA

-0.2%

ROIC

-2.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$823.4M$14.4M$
Q4 null$977.2M$26.0M$
FY null$3.44B$-8.6M$
Q3 null$860.5M$-59.6M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$50.13

Target (Median)

$51.50

Target Range

$35.00 - $60.00

2 Strong Buy7 Buy4 Hold1 Sell0 Strong Sell
UBSNeutral
2026-05-07
CitigroupNeutral
2026-05-07
BarclaysOverweight
2026-05-07
TD CowenHold
2026-05-07
GuggenheimBuy
2026-03-30

Trading Activity

Insider Trades

View All
Bernard Thierrydirector
SellTue May 19
Munch Markofficer: EXEC VP&PRES BRUKER NANO INC.
SellMon May 18
Munch Markofficer: EXEC VP&PRES BRUKER NANO INC.
SellMon May 18
Munch Markofficer: EXEC VP&PRES BRUKER NANO INC.
SellThu Apr 16
Munch Markofficer: EXEC VP&PRES BRUKER NANO INC.
SellThu Apr 16

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.12

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Peers